Meta Pixel

News and Announcements

Vale Steven Peuschel OAM

  • Published November 20, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Vale Steven Peuschel OAM

It is with great sadness that we inform you of the passing of our colleague and friend, Steven Peuschel. Steve passed away on 7 November 2017 after a short but brave battle with late stage cancer. The entire 4Dx team sends our most heartfelt condolences and sympathy to his family and friends.

Steve was an extraordinary person who dedicated much of his life to improving healthcare. Over many years Steve worked with The Alfred hospital to raise awareness and desperately needed funds to address the significant shortcomings in the fields of respiratory medicine and organ transplant. Steve’s contribution to the development of new programs and protocols in these areas continues to provide positive health outcomes for many people.

Steve joined 4Dx on 5 January 2015 and as Executive Director and Senior Vice President, engaged with key opinion leaders and investors to ensure 4Dx had the knowledge, contacts and resources required take our technology to the clinic. Steve’s expertise, passion, positive attitude, and work ethic had an immediate and everlasting impact on 4Dx.

Steve will be profoundly missed not only by all at 4Dx, but also by our community as a whole. His humor, strength, character, tenacity, integrity, and charm will always be remembered, and his impact in the healthcare space will be felt for generations to come.

Sorely missed. Never Forgotten.

On behalf of Wholesale Investor, we would like to send our best wishes to the Peuschel Family. Steve was one of the most passionate and driven people we had the opportunity to work with. His dedication to the 4Dx mission inspired many and was created from his own lifelong challenges with health.

Thank you, Steve, for the opportunity to work with you and the 4Dx team. We hope that in your passing, we can assist in fulfilling the mission you were a part of creating.

Capital Insights
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be  Attracting Big Pharma’s Attention

Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Join over 45,000+ sophisticated investors

Join Now